Publications of Sobha Kurian, MD

Radiation exposure from diagnostic procedures in patients with newly diagnosed breast cancer.
Chaudhary LN, Knapp S, Wen S, Xiao J, Marano GD, Kurian S, Layne G, Jacobson GM, Abraham J.
J Community Support Oncol. 2015;13(1):27-29.

Exercise and dietary advice intervention for survivors of triple-negative breast cancer: effects on body fat, physical function, quality of life, and adipokine profile.
Swisher AK, Abraham J, Bonner D, Gilleland D, Hobbs GR, Kurian S, Yanosik MA, Vona-Davis LC.
Support Care Cancer. 2015;23(10):2995-3003.


Weight change associated with third-generation adjuvant chemotherapy in breast cancer patients.
Chaudhary LN, Wen S, Xiao J, Swisher AK, Kurian S, Abraham J.
J Community Support Oncol. 2014;12(10):355-360.

Health behaviors among breast, prostate, and colorectal cancer survivors: a US population-based case-control study, with comparisons by cancer type and gender.
Lemasters TJ, Madhavan SS, Sambamoorthi U, Kurian S.
J Cancer Surviv. 2014;8(3):336-348.

Breast cancer pathology, receptor status, and patterns of metastasis in a rural Appalachian population.
Vona-Davis LC, Rose DP, Gadiyaram V, Ducatman BS, Hobbs GR, Hazard HW, Kurian S, Abraham J.
J Cancer Epidemiol. 2014;2014:170634


Bone marrow osteoblast vulnerability to chemotherapy.
Gencheva M, Hare I, Kurian S, Fortney JE, Piktel D, Wysolmerski RB, Gibson LF.
Eur J Haematol. 2013;90(6):469-478.


A population-based study comparing HRQoL among breast, prostate, and colorectal cancer survivors to propensity score matched controls, by cancer type, and gender.
Lemasters TJ, Madhavan SS, Sambamoorthi U, Kurian S.
Psychooncology. 2013;22(10):2270-2282.

Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways.
Provenzano A, Kurian S, Abraham J.
Expert Rev Anticancer Ther. 2013;13(2):143-147.

Initial clinical test of a breast-PET scanner.
Raylman RR, Abraham J, Hazard HW, Koren C, Filburn S, Schreiman JS, Kurian S, Majewski S, Marano GD.
J Med Imaging Radiat Oncol. 2011;55(1):58-64.


Prognostic significance of the "surprise" question in cancer patients.
Moss AH, Lunney JR, Culp SL, Auber ML, Kurian S, Rogers JS, Dower JM, Abraham J.
J Palliat Med. 2010;13(7):837-840.

Concordance between substance P levels and antiemetic guidelines.
Higa GM, Auber ML, Altaha R, Kurian S, Hobbs GR.
J Support Oncol. 2009;7(4):138-142.

Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.
Oostendorp RL, Loftiss J, Goel S, Smith DA, Dar MM, Witteveen PO, Cohen RB, Lewis LD, Kurian S, Patnaik A, Rosing H, Beijnen JH, Voest EE, Burris H, Schellens JH.
Int J Clin Pharmacol Ther. 2009;47(3):195-206.

CA 27-29 in patients with breast cancer with pulmonary fibrosis.
Kurian S, Khan M, Grant M.
Clin Breast Cancer. 2008;8(6):538-540.

5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Higa GM, Auber ML, Altaha R, Piktel D, Kurian S, Hobbs GR, Landreth KS.
J Oncol Pharm Pract. 2006;12(4):201-209.

Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit.
Kurian S, Qazilbash MH, Fay J, Wolff S, Herzig R, Hobbs GR, Bunner P, Weisenborn R, Aya-Ay M, Lynch JP, Ericson SG.
Breast J. 2006;12(6):531-535.

Esthesioneuroblastoma in Maffucci's syndrome.
Kurian S, Ertan E, Ducatman BS, Crowell EB, Rassekh CH.
Skeletal Radiol. 2004;33(10):609-612.

Atypical t(15;17)(q13;q12) in a patient with all-trans retinoic acid refractory secondary acute promyelocytic leukemia: a case report and review of the literature.
Kurian S, Hogan TF, Bleigh OC, Dowdy YG, Merghoub T, Pandolfi PP, Wenger SL.
Cancer Genet Cytogenet. 2002;138(2):143-148.